pyridostigmine pretreatment for nerve agent for aviation per

File: 081296_may96_decls14_0002.txt
Page: 0002
Total Pages: 3

Subject: pyridostigmine pretreatment for nerve agent for aviation per    

Box  ID: BX001424

Document Number:          2

Folder Title: INCOMING MSG  -  DESERT SHIELD  CHEM                                                            

Folder Seq #:        198

Unit: 24TH ID     

Parent Organzation: XVIII CORPS 






                             UNCLASSIFIED

                                                            PT05499 PAGE' 02
         PRIORITY                                     CORRECTED COPY*******




         INFO RUEADWD/HODA WASH//SGPS-PSP/DASG-HCO-0
         RUEABOL/HG USAF BOLLING AFB WASHOC//SGHR//
         RULSSUA/BUMED WASH DC//MED-02C/23//
         RULNAPG/CDRUSAMRICD ABERDEEN PROVING GROUND
         /MD//SGRO-UV-ZA//
         ST

         SU-          Y.Rlf)OSTIGMINE PRETREATMENT FOR NERVE AGTNT FOR AVIATION
                     PERSONNEL
         1.   (U) INQUIRIES TO OTSG HAVE INDICATED A NEED FOR GUIDANCE ON THE
         SAFETY AND EFFICACY OF USING PYRIDOSTIGMINE BROMIDE IN THE




         PAGE 02 RUEADWO0003
         ,PRETREATMENT OF AVIATION PERSONNEL IN AN ENVIRONMENT THAT MAY BECOME
         OR IS ALREADY CONTAMINATED WITH NERVE AGENT(S).
         2.   (U) THE SURGEON 6ENERAL'S GUIDANCE IS THAT THE PROCEDURES IN F14
         ,8-285 FOR THE USAGE OF PYRIDOSTIGMINE PRETREATMENT WILL BE
         FOLLOWED FOR AVIATION PERSONNEL.    IT IS A COMMAND RESPONSIBILRTY TO
         DECIDE WHETHER TO BEGIN* CONTINUE OR DISCONTINUE THE NERVE AGENT
         PYRIDOSTISMINE PRETREATMENT (NAPP).
         3. (U) PYRIDOSTIGMINE WILL BE ADMINISTERED TO AIRCREWS-AT A DOSE OF
         30 MILLIGRAMS EVERY EIGHT HOURS.    PRETESTING OF AVIATION PERSONNEL TO
         DETERMINE ADVERSE EFFECTS IS NOT REQUIRED.
         4.   (U) DETRIMENTAL SIDE EFFECTS ARE UNCOMMONT BUT INCLUDE HEADACKE9
         SKIN RA-SHV ABDOMINAL CRAMPS* CIARRHEAV NAUSEAT MUSCLE WEAKNESS AND
         CRAMPS* AND DIMNESS OF VISION DUE TO PUPILLARY CONSTRICTION.      MOST
         SYMPTOMS ARE CAUSED BY OVEROOSAGE INCLUDING DOUBLE DOSING TO MAKE UP
         FOR MISSED DOSES.   DISCONTINUING PYRIDOSTIGNINE SHOULD ALLEVIATE THE
         SIGNS AND SYMPTOMS OF MOST ADVERSE REACTIONS BUT ATROPINE MAY BE
         REQUIRED FOR SEVERE CASES.
         5.   tN AIRCREW PERFORMANCE DEGRADATION IS MINIMAL TO RARE WHEN
COMMENDED DOSAGE.     KNOWN SIDE
         EFFECTS OF AEROMEDICAL SIGNIFICANCE INCLUDE DOUBLE VISION* BLURRED




         PAGE 03 RUEADWO0003
         VISIONP INCREASED TEARING/SALIVATION* AND GASTROINTESTINAL UPSETS.
         THESE  SY14PTOMS ARE DOSE RELATED AND RARELY SEEN ON THE RECOMMENDED
         REGIMEN@ BUT MUST BE MONITORED BY AVIATION MEDICINE PERSONNEL.
         PYRIDOSTISMINE DOES NOT APPEAR TO AFFECT MOOD* ONSET OF FATIGUE9 CREW
         C OORD INA7 10 Nt FLIGHT PERFORMANCE, MISSION COMPLETIONP NAVIGATIONAL
         AND TARGET ACCURACY9 PERFORMANCE OF COMPLEX TASKS* AND VISUAL-MOTOR
         COORDINATION. SOME DEGRADATION IN UNAIDED NIGHT visron AND AN
         INCREASE IN SWEATING SHOULD BE EXPECTED* BUT THIS SHOULD NOT
         INTERFERE WITH MISSION COMPLETION.



         PRIORITY                                     CORRECTED COPY*******


                              UNCLASSIFIED

Document 3 f:/Week-21/BX001424/INCOMING MSG - DESERT SHIELD CHEM/pyridostigmine pretreatment for nerve agent for :08099611160251
Control Fields 17
File Room = may96_declassified
File Cabinet = Week-21
Box ID = BX001424
Unit = 24TH ID
Parent Organization = XVIII CORPS
Folder Title = INCOMING MSG - DESERT SHIELD CHEM
Folder Seq # = 198
Subject = PYRIDOSTIGMINE PRETREATMENT FOR NERVE AGENT FOR
Document Seq # = 51
Document Date =
Scan Date = 28-MAY-1996
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 09-AUG-1996